

# Corneal Collagen Cross-Linking

**Policy Number:** CS354.B  
**Effective Date:** April 1, 2024

[Instructions for Use](#)

Table of Contents	Page
<a href="#">Application</a> .....	1
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Definitions</a> .....	1
<a href="#">Applicable Codes</a> .....	2
<a href="#">Description of Services</a> .....	2
<a href="#">Clinical Evidence</a> .....	3
<a href="#">U.S. Food and Drug Administration</a> .....	8
<a href="#">References</a> .....	8
<a href="#">Policy History/Revision Information</a> .....	9
<a href="#">Instructions for Use</a> .....	9

Commercial Policy
<ul style="list-style-type: none"> <li><a href="#">Corneal Collagen Cross-Linking</a></li> </ul>

## Application

This Medical Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted:

State	Policy/Guideline
Indiana	None
Kentucky	<a href="#">Corneal Collagen Cross-Linking (for Kentucky Only)</a>
Louisiana	None
New Jersey	<a href="#">Corneal Collagen Cross-Linking (for New Jersey Only)</a>
New Mexico	<a href="#">Corneal Collagen Cross-Linking (for New Mexico Only)</a>
North Carolina	None
Ohio	<a href="#">Corneal Collagen Cross-Linking (for Ohio Only)</a>
Pennsylvania	<a href="#">Corneal Collagen Cross-Linking (for Pennsylvania Only)</a>
Tennessee	<a href="#">Corneal Collagen Cross-Linking (for Tennessee Only)</a>

## Coverage Rationale

Corneal Collagen Cross-Linking (C-CXL) using an Epithelium-Off approach, riboflavin (vitamin B2), and ultraviolet A is proven and medically necessary for the treatment of the following indications:

- [Progressive Keratoconus](#)
- [Corneal Ectasia](#) resulting from refractive surgery in individuals who have failed conservative treatment (e.g., rigid contact lens, spectacle correction)

C-CXL is unproven and not medically necessary for all other indications or using any other methods due to insufficient evidence of efficacy.

## Definitions

**Accelerated Corneal Collagen Cross-Linking (CXL):** A variation of Epithelium-Off Corneal Collagen Cross-Linking or Epithelium-On Corneal Collagen Cross-Linking in which the irradiance of ultraviolet A (UVA) light is increased and the procedure duration is decreased (American Academy of Ophthalmology, 2016).

**Corneal Collagen Cross-Linking Plus (CXL-Plus):** Performance of Epithelium-Off Corneal Collagen Cross-Linking or Epithelium-On Corneal Collagen Cross-Linking in combination with other refractive eye procedures such as intrastromal corneal ring segments, or topography-guided photorefractive keratectomy (PRK) (American Academy of Ophthalmology, 2021).

**Corneal Ectasia:** A forward bulging and thinning of the cornea. It may result from a disease of the cornea (e.g., Keratoconus), trauma, atrophy, raised intraocular pressure, or as a complication of photorefractive surgery, in which the corneal stroma has been left thinner than about 250 µm (American Academy of Ophthalmology, 2021).

**Epithelium-Off Corneal Collagen Cross-Linking (CXL):** The conventional method of performing the CXL procedure. After de-epithelializing the central (7-9 mm) cornea, riboflavin activated by UVA light is used to generate reactive oxygen species that interact with collagen in the corneal stroma. Also referred to as the Dresden Protocol (American Academy of Ophthalmology, 2017).

**Epithelium-On Corneal Collagen Cross-Linking (CXL):** A modification of Epithelium-Off Corneal Collagen Cross-Linking in which the corneal epithelium is left intact prior to instilling the eye with riboflavin followed by exposure to UVA light. Also referred to as transepithelial Corneal Collagen Cross-Linking (American Academy of Ophthalmology, 2017).

**Keratoconus:** A common corneal disorder in which the central or paracentral cornea undergoes progressive thinning and steepening causing irregular astigmatism (American Academy of Ophthalmology, 2017).

**Progressive Keratoconus:** Defined as one or more of the following:

- An increase of 1 diopter (D) in the steepest keratometry value
- An increase of 1 D in regular astigmatism evaluated by subjective manifest refraction
- A myopic shift (decrease in the spherical equivalent) of 0.50 D on subjective manifest refraction
- A decrease  $\geq 0.1$  mm in the back optical zone radius in rigid contact lens wearers where other information was not available (American Academy of Ophthalmology, 2017)

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
0402T	Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)

*CPT® is a registered trademark of the American Medical Association*

HCPCS Code	Description
J2787	Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL

## Description of Services

Keratoconus is a noninflammatory, degenerative eye condition characterized by progressive steepening and thinning of the normally round cornea into a cone shape. This abnormal shape prevents light entering the eye from focusing directly on the retina, resulting in irregular astigmatism and progressive myopia or visual loss. These changes lead to decreased visual acuity (distorted or blurred vision) and sensitivity to light or glare. The condition typically presents itself during adolescence or early adulthood. Although usually a bilateral disease, individuals may experience asymmetric symptoms with one eye more severely affected. Initial interventions generally include glasses or soft contact lenses, but as Keratoconus progresses, an individual may require fitting with rigid gas permeable or other types of contact lenses (Mastropasqua, 2015).

Corneal Ectasia is a noninflammatory condition, the hallmark of which is progressive corneal steepening and thinning that has been associated with refractive surgery, especially laser-assisted in situ keratomileusis (LASIK). Ectasia is a form of Keratoconus, a progressive disorder in which the cornea thins and begins to bulge into a cone-like shape. It can

significantly affect vision since the altered shape deflects light away from the retina. Types of Corneal Ectasia include Keratoconus, pellucid marginal degeneration, keratoglobus, post keratorefractive ectasia, and wound ectasia after penetrating keratoplasty (PK). Corneal Ectasias are associated with decreased uncorrected visual acuity (UCVA), an increase in ocular aberrations, and often a loss of best-corrected distance visual acuity (BCVA). Treatment options for ectasia include intraocular pressure-lowering drugs, and intracorneal ring segments. Frequently, a penetrating keratoplasty is required. None of the currently available treatment options for Keratoconus and Corneal Ectasia halt the progression of disease and corneal transplantation is the only option available when functional vision can no longer be achieved (Feder et al., 2013).

Refractive surgery refers to surgical procedures designed to correct refractive errors by reshaping the corneal surface, and to improve the focusing power of the eye, thus reducing or eliminating the need for corrective lenses. According to the AAO, refractive surgery is an elective procedure which may be considered by those who wish to become less dependent on spectacles or contact lenses or when there is an occupational or cosmetic reason to not wear spectacles (AAO, 2017).

Refractive surgery, particularly laser-assisted in situ keratomileusis (LASIK), is a common cause of Corneal Ectasia. LASIK reshapes the surface of the cornea with an excimer laser to focus visual images directly onto the retina and improve visual acuity. Post-LASIK corneal ectasis is a serious side effect that involves progressive thinning and steepening of the central and inferior portions of the cornea (Hayes, 2017, updated 2022).

The main objective of Corneal Collagen Cross-Linking (CXL) is to achieve strengthening of corneal tissue as a means to stop further progression of Keratoconus or Corneal Ectasia. In order to induce cross-links within and between collagen fibers of corneal stroma, long-wave ultraviolet A (UVA) radiation (370 nm) is used combined with a chromophore (riboflavin, vitamin B2). Riboflavin acts as photosensitizer that when exposed to UVA is activated, producing oxygen free radicals that initiate the creation of those new covalent bonds bridging the amino groups of collagen fibrils and possibly other corneal macromolecules, such as proteoglycans and nucleic acids. This photopolymerization process results in the increased rigidity of corneal tissue (Galvis et al., 2017).

As mentioned above Corneal Collagen Cross-Linking (CXL) has the potential to slow the progression of disease. It is performed with the photosensitizer riboflavin (vitamin B2) and ultraviolet A (UVA) irradiation. There are 2 protocols for CXL.

- Epithelium-Off CXL (also known as “epi-off”): In this method, about 8 mm of the central corneal epithelium is removed under topical anesthesia to allow better diffusion of the photosensitizer riboflavin into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea (every 1-3 minutes for 30 minutes) until the stroma is completely penetrated. The cornea is then irradiated for 30 minutes with ultraviolet A 370 nm, a maximal wavelength for absorption by riboflavin, while the riboflavin continues to be applied. The interaction of riboflavin and UVA causes the formation of reactive oxygen species, leading to additional covalent bonds (cross-linking) between collagen molecules, resulting in stiffening of the cornea. Theoretically, by using a homogeneous light source and absorption by riboflavin, the structures beyond a 400-micron thick stroma (endothelium, anterior chamber, iris, lens, retina) are not exposed to an ultraviolet dose that is above the cytotoxic threshold
- Epithelium-On CXL (also known as “epi-on” or transepithelial): In this method, the corneal epithelial surface is left intact (or may be partially disrupted) and a longer riboflavin loading time is needed. CXL is being evaluated primarily for corneal stabilization in patients with progressive corneal thinning, such as Keratoconus and Corneal Ectasia following refractive surgery. CXL may also have anti-edematous and antimicrobial properties (ECRI, 2018)

## Clinical Evidence

### Corneal Collagen Cross-Linking (C-CXL) Using an Epithelium-Off Approach

#### *Keratoconus*

In a prospective, multicenter randomized controlled trial (RCT), Hersh et al. (2017a) evaluated the safety and efficacy of corneal collagen crosslinking (CXL) for the treatment of progressive keratoconus (n = 205). The treatment group underwent standard CXL and the sham control group received riboflavin alone without removal of the epithelium. The primary efficacy criterion was the change over 1 year of topography-derived maximum keratometry value, comparing treatment with control group. Secondary outcomes evaluated were corrected distance visual acuity (CDVA), uncorrected distance visual acuity (UDVA), manifest refraction spherical equivalent, endothelial cell count, and adverse events. In the CXL treatment group, the maximum keratometry value decreased by 1.6 diopters (D) from baseline to 1 year, whereas keratoconus continued to progress in the control group. In the treatment group, the maximum keratometry value decreased by 2.0 D or more in 28 eyes (31.4%) and increased by 2.0 D or more in 5 eyes (5.6%). The CDVA improved by an average of 5.7 logarithm of the minimum angle of resolution (logMAR) units. Twenty-three eyes (27.7%) gained and 5 eyes lost (6.0%) 10 logMAR or more. The UDVA improved 4.4 logMAR. Corneal haze was the most frequently reported

CXL-related adverse finding. There were no significant changes observed by the authors in endothelial cell count 1 year after treatment. Corneal collagen crosslinking was effective in improving the maximum keratometry value, CDVA, and UCVA in eyes with progressive keratoconus 1 year after treatment, with an excellent safety profile.

In a systematic review and meta-analysis of CXL in pediatric patients with keratoconus, McAnena et al. (2017) evaluated primary outcomes of uncorrected visual acuity (UCVA) and maximum keratometry (Kmax), and secondary outcomes of best-corrected visual acuity (BCVA), mean refractive spherical equivalent (MRSE), central corneal thickness (CCT) and endothelial cell density (ECD). Standardized mean differences (SMD) and 95% confidence intervals were calculated, comparing baseline values with those at 6, 12 and 24 months. A total of 13 papers, published between May 2011 and December 2014, examining 490 eyes of 401 patients with a mean age of 15.25 ( $\pm 1.5$ ) years, were included in the qualitative analysis in this review and included both epithelium-on and epithelium-off procedures. Nine papers were included in the meta-analysis, showing significant improvement in UCVA and BCVA and stable Kmax at 12 months, and stable UCVA, improved BCVA and improved Kmax at 24 months in the standard protocol group UCVA, BCVA and Kmax were stable at 12 months in the trans-epithelial group. In conclusion, it was found that standard CXL may be effective in halting progression of keratoconus in pediatric patients at 1 year. However, larger, more long-term studies are required to ascertain its effectiveness. All studies were limited by an observational design without comparison groups, which could introduce a bias in the findings.

Li et al. (2015) conducted a meta-analysis of RCT to evaluate the efficacy of CXL for the treatment of keratoconus. The primary outcome measures included changes of topographic parameters, visual acuity, and refraction. Efficacy estimates were evaluated by weighted mean difference (WMD) and 95% confidence interval (CI) for absolute changes of the interested outcomes. A total of six RCTs fulfilling the eligibility criteria were included, with a total of 179 eyes in the CXL group, and 182 eyes included in the control group. Duration of follow-up ranged from three months to 36 months. In the authors' opinion, their findings indicate that CXL is safe and effective for the treatment of keratoconus, which results in significant reductions in corneal topographic measurements, manifest cylinder error, and improvement in visual outcomes. Further studies with long-term duration and larger sample size will be necessary to conclude in stabilization and absence of iatrogenicity for CXL.

Hashemi et al. (2014) reported 5-year results on conventional CXL performed on 32 patients (40 eyes) with progressive keratoconus. During the 1<sup>st</sup> year, the mean-K, max-K, UCVA, and astigmatism showed no change over time during these 5 years. After the first year, BCVA, MRSE, and CCT showed no change and stabilized, whereas elevation readings continued to decrease up to 5 years after CXL. Based on the results, the authors concluded that treatment of keratoconus with CXL can stop disease progression, without raising any concern for safety, and can eliminate the need for keratoplasty. The study is limited by lack of comparison group.

Wittig-Salva et al. (2014) reported 3-year outcomes after CXL in the refractive, topographic, and clinical outcomes from a prospective RCT in 94 eyes with progressive keratoconus. The primary outcome measure was the maximum simulated keratometry value (Kmax). In control eyes (n = 48), Kmax increased by a mean of 1.20  $\pm$  0.28 diopters (D), 1.70  $\pm$  0.36 D, and 1.75  $\pm$  0.38 D at 12, 24, and 36 months, respectively (all p < 0.001). In treated eyes (n = 46), Kmax flattened by -0.72  $\pm$  0.15 D, -0.96  $\pm$  0.16 D, and -1.03  $\pm$  0.19 D at 12, 24, and 36 months, respectively (all p < 0.001). The treated eyes also showed improvements in secondary outcomes which included uncorrected visual acuity [UCVA; measured in logarithm of the minimum angle of resolution (logMAR) units], and best spectacle-corrected visual acuity (BSCVA; measured in logMAR units), as compared to control eyes. At 36 months, there was a sustained improvement in Kmax, UCVA, and BSCVA after CXL, whereas eyes in the control group demonstrated further progression.

## **Clinical Practice Guidelines**

### ***American Academy of Ophthalmology (AAO)***

In 2021, the American Academy of Ophthalmology updated their preferred practice pattern guidelines for C-CXL. They concluded that C-CXL has long-term data supporting its safety and stability and should be considered for patients with early keratoconus and at risk of progression, to arrest or slow progression in its earliest stage.

### ***National Institute for Health and Care Excellence (NICE)***

According to the 2013 National Institute for Health and Care Excellence (NICE), there is adequate evidence on the safety and efficacy of epithelium-off CXL using riboflavin and ultraviolet.

## **Corneal Ectasia Following Refractive Surgery**

In the pivotal prospective, multicenter RCT Hersh et al. (2017b) evaluated the safety and efficacy of CXL for the treatment of corneal ectasia after laser refractive surgery. The patient population was 179 subjects with corneal ectasia after previous refractive surgery. The treatment group underwent standard CXL, and the sham control group received riboflavin

alone without removal of the epithelium. In the crosslinking treatment group, the maximum K value decreased by 0.7 diopters (D) from baseline to 1 year, whereas there was continued progression in the control group (1.3 D difference between treatment and control,  $p < 0.0001$ ). In the treatment group, the maximum K value decreased by 2.0 D or more in 14 eyes (18%) and increased by 2.0 D or more in 3 eyes (4%). The CDVA improved by an average of 5.0 logarithm of the minimum angle of resolution (logMAR) letters. Twenty-three eyes (32%) gained and 3 eyes (4%) lost 10 or more logMAR letters. The UDVA improved 4.5 logMAR letters. Corneal haze was the most frequently reported crosslinking-related adverse finding. The authors concluded that CXL was effective in improving the maximum K value, CDVA, and UDVA in eyes with corneal ectasia 1 year after treatment, with an excellent safety profile. Additional RCTs with longer-term outcomes are needed to evaluate the efficacy of CXL for this indication.

Wan et al. (2017) conducted a systematic review and meta-analysis to review the safety and stability of CXL for the treatment of keratectasia after excimer laser refractive surgery. Seven studies involving 118 patients treated with CXL for progressive ectasia after laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK) (140 eyes; the follow-up time range from 12 to 62 months) were included in the meta-analysis. The primary outcome parameters included the changes of corrected distant visual acuity (CDVA), uncorrected visual acuity (UCVA), the maximum keratometry value (Kmax) and minimum keratometry value (Kmin), the surface regularity index (SRI), the surface asymmetry index (SAI), the keratoconus prediction index (KPI), corneal thickness, and endothelial cell count. Efficacy estimates were evaluated by weighted mean difference (WMD) and 95% confidence interval (CI) for absolute changes of the interested outcomes. The authors concluded that CXL is a promising treatment to stabilize the keratectasia after excimer laser refractive surgery. Further long-term follow-up studies are necessary to assess the persistence of the effect of the CXL. Study limitations include variation in patient population, follow-up periods, clinical measurement and quality, as well as lack of comparison to a different treatment.

## **Clinical Practice Guidelines**

### **American Academy of Ophthalmology (AAO)**

The AAO's 2017 Preferred Practice Pattern on external diseases of the cornea includes corneal collagen crosslinking as a potential surgical treatment for cornea ectasia, noting that the procedure can improve corneal rigidity by increasing bonds between fibers. AAO stated that options for the treatment of corneal ectasia after LASIK include corneal crosslinking. Studies have shown that CXL induced by topical riboflavin and ultraviolet irradiation may arrest keratectasia, as demonstrated by preoperative and postoperative corneal topography/tomography and a reduction in maximum keratometric readings. Long-term stability after CXL therapy for treatment of post-refractive corneal ectasia has been reported.

### **Accelerated Corneal Collagen Cross-Linking (A-CXL)**

Because of lack of precision, frequent indeterminate risk of bias due to inadequate reporting, and inconsistency in outcomes measured and reported among studies, it remains unknown whether A-CXL confers an advantage over conventional epithelium-off CXL for patients with progressive keratoconus with respect to further progression of keratoconus, visual acuity outcomes, and patient-reported outcomes (PROs). Furthermore, methods of assessing and defining progressive keratoconus should be standardized. Trials with longer follow-up are required in order to assure that outcomes are measured after corneal wound-healing and stabilization of keratoconus.

Shajari et al. (2019) conducted a systematic review and meta-analysis to compare the results of conventional corneal crosslinking (C-CXL) and accelerated corneal crosslinking (A-CXL) for the treatment of keratoconus. Twenty two studies including fourteen prospective randomized controlled trials, four prospective nonrandomized comparative studies and four retrospective reviews met the inclusion criteria. The primary outcomes were measured changes in uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), spherical equivalent (SE), spherical and cylindrical error, central and minimum corneal resistance factor (CRF), anterior stromal keratocyte density, sub-basal nerve density, endothelial cell density (ECD), percentage of hexagonal endothelial cells, as well as average, maximal and minimal keratometry values. There was no statistically significant difference in uncorrected distance visual acuity, corrected distance visual acuity, spherical equivalent, spherical error, cylindrical error, maximal keratometry, average keratometry, central corneal thickness, corneal biomechanical properties, time of re-epithelialization, sub-basal nerve density, endothelial cell density and morphology. Study limitations included the use of heterogeneous A-CXL protocols (e.g., various duration, composition and frequency of riboflavin exposure) and all trials were weighed similarly regardless of study type. The authors concluded that C-CXL and A-CXL seem to provide comparable results in halting keratoconus. However, larger studies with longer follow up times are necessary to evaluate the long-term results of different A-CXL protocols compared to C-CXL.

Artola et al. (2017) conducted a prospective case series to evaluate accelerated transepithelial CXL in a total of 19 keratoconus eyes of 12 patients between 26 and 69 years of age. One month after surgery, a non-statistically significant

change was noted in sphere and in spherical equivalent, whereas a significant improvement was observed in corrected distance visual acuity. A significant change was observed in topographic astigmatism and posterior corneal a sphericity. In the authors' opinion, accelerated transepithelial CXL may be a useful technique for the management of progressive keratoconus. CXL maintained the topographic and aberrometric profile of the cornea without significant changes for a period of 12 months after the procedure. The authors recommend future studies to show the corneal biomechanical changes that occur in-vivo with the use of this technique. The findings are limited by lack of comparison group.

In a comparative, retrospective, consecutive case series of 78 eyes in 58 pediatric patients with keratoconus, Baenninger et al. (2017) evaluated visual and topographic outcomes 1 year after conventional (C-CXL) vs. accelerated corneal cross-linking (A-CXL). In this single-center analysis, 39 eyes underwent C-CXL and 39 eyes A-CXL. No subjects were lost to follow-up after 12 months. No significant difference between changes in 12 months after as compared to the time before CXL for UCVA (0.01 log MAR; 95% confidence interval -0.14 to 0.15,  $p = .944$ ), BCVA (0.05 log MAR; 95% confidence interval -0.05 to 0.15,  $p = .310$ ), and Kmax (-0.77 diopters; 95% confidence interval -2.20 to 0.65,  $p = .282$ ) between the C-CXL and A-CXL group were observed. Treatment failure rate was observed in 9 of 39 eyes (23.1%) in C-CXL and in 6 of 39 eyes (15.4%) in A-CXL ( $p = .389$ ). Adverse events were seen only in 1 eye in the C-CXL group. In this retrospective comparison, the authors concluded that the accelerated approach was equally as effective as the conventional protocol to treat pediatric keratoconus. However, the study was not designed and may not have been powered to demonstrate non-inferiority. Furthermore, lack of randomization may have led to biases. Randomized controlled trials with larger patient populations and longer follow-ups are needed to validate these findings.

Woo et al. (2017) compared the visual, refractive, topographic and biomechanical outcomes of conventional (CXL 3mW/cm<sup>2</sup> for 30 minutes) or accelerated cross linking (KXL; 30mW/cm<sup>2</sup> for 4 minutes) in a prospective, non-randomized interventional study of 76 patients with progressive keratoconus. At the 1-year follow-up, both groups showed no significant increase in K1, K2 and Kmean from baseline. There was also no difference between the CXL and KXL group for postoperative corneal topography as well as central and minimal pachymetry up to 12 months. There was a significant increase in both corneal hysteresis (0.62mm Hg,  $p = 0.04$ ) and corneal resistance factor (0.91mm Hg,  $p = 0.003$ ) in the KXL group at 12 months but not in the CXL group. There was no significant endothelial cell loss throughout follow up in both the groups. Although the authors' concluded that accelerated CXL provided a biochemical advantage, the study was not designed and may not have been powered to demonstrate non-inferiority. Lack of randomization may have led to biases.

Wang et al. (2017) conducted a comparative evaluation of progression rate in keratoconus with accelerated CXL. One hundred forty-five eyes were followed without CXL (no-CXL group) for a median duration of 31 months whereas 45 eyes were followed up for 41 months before (pre-CXL) and after (post-CXL) accelerated, epithelium-off CXL. Progression was defined based on significant slope found in linear mixed effect models against time. Swept-source optical coherence tomography was used for measurement of anterior steep keratometry, anterior flat keratometry (Ant Kf), anterior average keratometry (Ant Avg K); posterior steep keratometry, posterior flat keratometry (Post Kf), posterior average keratometry (Post Avg K) and corneal thickness. The patients in the pre-CXL group were significantly younger ( $26.3 \pm 5.48$  years) compared with the patients in no-CXL group ( $32.7 \pm 10.24$  years) ( $p = 0.004$ ). Significant differences were observed during baseline examination for all parameters ( $p \leq 0.035$ ) between pre-CXL and no-CXL groups except Ant Cyl and Post Cyl. During the observation period, statistically significant differences were noted between pre-CXL and no-CXL groups in the progression rate of Ant Kf, Ant Avg K, Post Kf and Post Avg K ( $p \leq 0.045$ ). After CXL, the progression rate in the post-CXL group was comparable to that in no-CXL group. All corneal parameters remained stable in the no-CXL group throughout the follow-up period. The authors observed a decrease in progression rate of corneal parameters after CXL. In cases with stable corneal parameters over time, careful monitoring can be considered instead of collagen crosslinking. The findings are limited by lack of randomization, which could have introduced biases and lack of comparison with proven therapies.

In a prospective, non-randomized study, Badawi (2016) evaluated the effects of accelerated CXL on corneal endothelium in keratoconus ( $n = 40$  eyes) and post-laser-assisted in situ keratomileusis (LASIK) ectasia ( $n = 10$  eyes). Over the course of 12 months (at 3 month intervals), qualitative and quantitative analyses of the corneal endothelial cells were conducted. There was a significant reduction in endothelial cell count particularly at 3 and 6 months post-CXL. In addition, the coefficient of variance was also statistically significantly higher at 3 and 6 months postoperatively than the pre-CXL value. There was a slight change in the percentage of hexagonal cells. In this patient population, the author concluded that the use of accelerated CXL (10 mW/cm<sup>2</sup> for 9 minutes) has a transient negative impact on endothelial cell density and/or endothelial morphology. The study is limited by lack of comparison group. Well-designed RCTs with larger patient populations and longer follow-up periods are needed to compare accelerated CXL to conventional CXL in terms of safety and efficacy.

## Epithelium-On Corneal Collagen Cross-Linking

Current evidence on the safety and efficacy of epithelium-on (transepithelial) CXL procedures for keratoconus and corneal ectasia is inadequate in quantity and quality. Further long-term follow-up studies are necessary to assess the persistence of the effect of the CXL using epithelium-on procedure. Study limitations include variation in patient population, follow-up periods, clinical measurement, and quality.

In an RCT, Rush and Rush (2017) compared the outcomes of CXL for the treatment of progressive corneal ectasia using a standard epithelium-off technique versus a transepithelial technique with enhanced riboflavin solution. One hundred forty-four eyes with progressive corneal ectasia were prospectively randomized into a transepithelial CXL study arm or an epithelium-off CXL control arm. Follow-up examinations were set at 3, 6, 12 and 24 months. The primary outcome measure was change in the maximum simulated keratometry value (Ksteep) after 24 months of follow-up. The secondary outcome measure was change in the best spectacle-corrected visual acuity (BSCVA) after 24 months follow-up. One hundred and thirty-one eyes completed the 24 month follow-up interval. Change in Ksteep was  $-1.52 \pm 0.66$  diopters (D) for the control group versus  $-0.54 \pm 0.58$  D for the study group at 24 months of follow-up ( $p = 0.0320$ ). Change in BSCVA was  $-0.18 \pm 0.09$  logMAR for the control group versus  $-0.14 \pm 0.08$  logMAR for the study group at 24 months of follow-up ( $p = 0.4978$ ). Two eyes in the control group had minor postoperative complications that did not affect the final visual acuity, and one eye in the control group underwent keratoplasty during the study interval. At 24 months of follow-up, subjects in the epithelium-off CXL group demonstrated a greater improvement in Ksteep compared with subjects in the transepithelial CXL group, but no statistically significant difference in BSCVA was found between groups.

In a systematic review and meta-analysis, Li and Wang (2017) evaluated the efficacy and safety of transepithelial CXL versus standard CXL on keratoconus. Three trials involving 244 eyes were evaluated, with 111 eyes in the standard CXL group and 133 eyes in the transepithelial CXL group. The pooled results showed that there were significant differences between the two groups in maximum keratometry (mean difference = 1.05 D, 95% CI 0.19 to 1.92,  $p = 0.02$ ), with the standard CXL is more effective in decreasing the maximum keratometry at least 12 months after operation; the transepithelial CXL group gained more improvement in CDVA (mean difference =  $-0.07$ , 95% CI  $-0.12$  to  $-0.02$ ,  $p = 0.007$ ); there were no significant differences in uncorrected distant visual acuity (UDVA) between the two groups (mean difference =  $-0.03$ , 95% CI  $-0.20$  to  $0.15$ ,  $p = 0.75$ ). A similar change was found in corneal thickness (mean difference =  $4.35$ , 95% CI  $-0.43$  to  $9.13$ ,  $p = 0.07$ ). The authors concluded that standard CXL is more effective in decreasing the maximum keratometry than the transepithelial CXL; the transepithelial CXL provided favorable visual outcomes; they both exhibit similar safety.

Bikbova and Bikbov (2016, included in the systematic review by Li and Wang) conducted an RCT of 149 eyes of 119 patients with keratoconus I-II of Amsler classification. Patients were divided into two groups: (1) 73 eyes with standard crosslinking (CXL) and (2) 76 eyes with transepithelial iontophoresis-assisted CXL. Depending on the group, epithelium removal or administration of riboflavin solution by iontophoresis for 10 min was performed, after which standard surface UVA irradiation (370 nm, 3 mW/cm<sup>2</sup>) was performed at a 5 cm distance for 30 min. The authors concluded that transepithelial iontophoresis-assisted collagen crosslinking was less effective than standard CXL after 24 months of follow-up, possibly due to a more superficial formation of corneal collagen crosslinks; however, the stopping of disease progression was achieved 24 months after procedure.

## Corneal Collagen Cross-Linking Plus (CXL-Plus)

Current evidence on the safety and efficacy of the combination (CXL-plus) procedures for keratoconus and keratectasia is inadequate in quantity and quality.

Al-Amri (2018) reported 5-year results from a prospective, interventional, non-randomized, and non-controlled case series in which 60 eyes with mild, non-progressive keratoconus were treated with combined non-topography guided (TG) photorefractive keratectomy (PRK) and CXL. Refraction, uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA), flat and steep keratometry readings, and adverse events were evaluated preoperatively and postoperatively. All study parameters showed a statistically significant improvement at 5y over baseline values. The author concluded that combined non-TG-PRK+CXL demonstrates positive 5-year outcomes in patients with mild, stable keratoconus. The findings are limited by lack of comparison groups. Based on these findings, the author recommends conducting future large scale, comparative, randomized trials with extended duration of follow-up to establish the long-term stability of this procedure in keratoconus.

Kontadakis et al. (2016) compared the results of CXL alone with combined simultaneous topography-guided photorefractive keratectomy plus CXL (tPRK-CXL) for progressive keratoconus for a 3-year interval (n = 60 eyes). Thirty eyes underwent combined tPRK with a solid-state laser (maximum ablation depth, 50  $\mu$ m) followed by CXL, and 30 eyes

underwent CXL alone. Groups were matched in terms of age and keratoconus stage. Corrected distance visual acuity (CDVA), uncorrected distance visual acuity (UDVA), keratometry, and corneal confocal microscopy were measured. In the authors' opinion, simultaneous tPRK followed by CXL in this series of keratoconus patients offered significantly improved vision to treated patients in comparison with CXL alone, and similar results regarding postoperative stability. The findings are, however, limited by lack of randomization, which could have introduced biases in the comparisons. Well-designed RCTs are needed to fully evaluate CXL-plus in the treatment of keratoconus.

## U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Corneal collagen cross-linking is a procedure and not subject to FDA regulations.

In 2016, riboflavin 5-phosphate in 20% dextran ophthalmic solution (Photrexa Viscous<sup>®</sup>; Avedro) and riboflavin 5-phosphate ophthalmic solution (Photrexa<sup>®</sup>; Avedro) were approved by the U.S. Food and Drug Administration for use with KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia after refractive surgery.

## References

Al-Amri AM. 5-year follow-up of combined non-topography guided photorefractive keratectomy and corneal collagen cross linking for keratoconus. *Int J Ophthalmol.* 2018 Jan 18;11(1):48-52.

American Academy of Ophthalmology (AAO). Corneal crosslinking. April 2016.

American Academy of Ophthalmology (AAO). EyeWiki. Keratoconus. 2017.

American Academy of Ophthalmology (AAO). Preferred Practice Pattern. Cornea/external disease summary. December 2020.

American Academy of Ophthalmology (AAO). Preferred Practice Pattern. Corneal ectasia. September 2018.

American Academy of Ophthalmology (AAO). Preferred Practice Pattern. Refractive Errors & Refractive Surgery. 2017.

Artola A, Piñero DP, Ruiz-Fortes P, et al. Clinical outcomes at one year following keratoconus treatment with accelerated transepithelial cross-linking. *Int J Ophthalmol.* 2017 Apr 18;10(4):652-655.

Badawi AE. Corneal endothelial changes after accelerated corneal collagen cross-linking in keratoconus and post-LASIK ectasia. *Clin Ophthalmol.* 2016 Sep 30;10:1891-1898.

Baenninger PB1, Bachmann LM, Wienecke L, et al. Pediatric corneal cross-linking: comparison of visual and topographic outcomes between conventional and accelerated treatment. *Am J Ophthalmol.* 2017 Nov;183:11-16.

Bikbova G, Bikbov M. Standard corneal collagen crosslinking versus transepithelial iontophoresis-assisted corneal crosslinking, 24 months follow-up: randomized control trial. *Acta Ophthalmol.* 2016;94(7):e600-e606.

ECRI Institute. Clinical Evidence Assessment. Corneal collagen cross-linking for treating keratoconus and corneal ectasia. January 2018. Updated February 2019.

Feder RS, McLeod SD, Akpek EK, et al. American Academy of Ophthalmology (AAO) Cornea/External Disease Preferred Practice Pattern (PPP) Panel, Hoskins Center for Quality Eye Care. Preferred practice pattern. Corneal ectasia. December 2021.

Garcia-Ferrer FJ, Akpek EK, Amescua G et al. American Academy of Ophthalmology Preferred practice pattern cornea and external disease panel. Corneal ectasia preferred practice pattern<sup>®</sup>. *Ophthalmology.* January 2019.

Hayes, Inc. Health Technology Assessment. Comparative Effectiveness Of Corneal Cross-Linking For Treatment Of Keratoconus. Hayes, Inc.; January 15, 2022.

Hayes, Inc. Medical Technology Directory. Conventional corneal collagen cross-linking for treatment of LASIK-related ectasia. Keratoconus Surgical Treatments. Hayes, Inc.; December 27, 2018. Updated February 4, 2022.

Hashemi H, et al. Corneal collagen cross-linking with riboflavin and ultraviolet a irradiation for keratoconus: long-term results. *Ophthalmology.* 2013;120(8):1515-20.

Hersh PS, Stulting RD, Muller D, et al. United States multicenter clinical trial of corneal collagen crosslinking for keratoconus treatment. *Ophthalmology.* 2017a Sep;124(9):1259-1270.



Hersh PS, Stulting RD, Muller D, et al. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia after refractive surgery. *Ophthalmology*. 2017b Oct;124(10):1475-1484.

Kontadakis GA, Kankariya VP, Tsoulneras K, et al. Long-term comparison of simultaneous topography-guided photorefractive keratectomy followed by corneal cross-linking versus corneal cross-linking alone. *Ophthalmology*. 2016;123(5):974-983.

Li J, Ji P, Lin X. Efficacy of corneal collagen cross-linking for treatment of keratoconus: a meta-analysis of randomized controlled trials. *PLoS One*. 2015 May 18;10(5):e0127079.

Li W, Wang B. Efficacy and safety of transepithelial corneal collagen crosslinking surgery versus standard corneal collagen crosslinking surgery for keratoconus: a meta-analysis of randomized controlled trials. *BMC Ophthalmol* 2017; 17(1):262.

Mastropasqua L. Collagen cross-linking: when and how? A review of the state of the art of the technique and new perspectives. *Eye Vis (Lond)*. 2015;2:19.

McAnena L, Doyle F, O'Keefe M. Cross-linking in children with keratoconus: a systematic review and meta-analysis. *Acta Ophthalmol*. 2017 May;95(3):229-239.

National Institute for Health and Care Excellence (NICE). Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia. September 2013.

Rush SW, Rush RB. Epithelium-off versus transepithelial corneal collagen crosslinking for progressive corneal ectasia: a randomised and controlled trial. *Br J Ophthalmol*. 2017 Apr;101(4):503-508.

Shajari M, Kolb CM, Agha B, et al. Comparison of standard and accelerated corneal cross-linking for the treatment of keratoconus: a meta-analysis. *Acta Ophthalmol*. 2019 Feb;97(1):e22-e35.

Wan Q, Wang D, Ye H, et al. A review and meta-analysis of corneal cross-linking for post-laser vision correction ectasia. *J Curr Ophthalmol*. 2017 Mar 15;29(3):145-153.

Wang YM, Chan TC, Yu MCY, et al. Comparative evaluation of progression rate in keratoconus before and after collagen crosslinking. *Br J Ophthalmol*. 2018 Aug;102(8):1109-1113.

Wittig-Silva C, Chan E, Islam FM, et al. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. *Ophthalmology*. 2014 Apr;121(4):812-21.

Woo JH, Iyer JV, Lim L, et al. Conventional versus accelerated collagen cross-linking for keratoconus: A comparison of visual, refractive, topographic and biomechanical outcomes. *Open Ophthalmol J*. August 2017;11:262-272.

## Policy History/Revision Information

Date	Summary of Changes
07/01/2024	<b>Application</b> <b>New Mexico</b> <ul style="list-style-type: none"><li>Added language to indicate this policy does not apply to the state of New Mexico; refer to the state-specific policy version</li></ul>
04/01/2024	<b>Supporting Information</b> <ul style="list-style-type: none"><li>Updated <i>Clinical Evidence</i> and <i>References</i> sections to reflect the most current information</li><li>Archived previous policy version CS354.A</li></ul>

## Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual<sup>®</sup> criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.